Summarizing efficacy data on tirzepatide, a novel glucose-lowering dual GIP/GLP-1 receptor agonist
What you need to know
The novel type 2 diabetes medication tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Its efficacy is being tested in the phase 3 SURPASS clinical trial program, with results of the cardiovascular outcomes study and a trial of tirzepatide in people with obesity but without diabetes expected in 2024. Explore this page for trial results and expert commentary, updated as new results are reported.
SURPASS-1 trial results & series summary
Trial series summary and independent commentary provided by John Wilding, University of Liverpool.
The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.
Researcher commentary provided by Juan Pablo Frías, National Research Institute, Los Angeles, USA
People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.
Researcher commentary provided by Francesco Giorgino, University of Bari Aldo Moro, Italy.
The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.
Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.
Researcher commentary provided by Michelle Welch, Diabetes and Metabolism Specialists, San Antonio, Texas, USA.
People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.
Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
